Literature DB >> 12570788

Blockade of apoptosis by ACE inhibitors and angiotensin receptor antagonists.

Gerasimos Filippatos1, Bruce D Uhal.   

Abstract

Inhibitors of angiotensin converting enzyme (ACE-Is) and angiotensin (ANG) receptor antagonists were originally developed to aid in the management of hypertension. As the use of these agents was extended to the management of heart failure and other cardiovascular diseases, studies of tissue remodeling suggested that blockade of ANGII function might play a role in the regulation of cell death by apoptosis. Experiments with cultured cells confirmed that ANGII is an inducer of apoptosis in well differentiated cell types isolated from the heart, kidneys, lungs and other organs. More recent evidence with animal models strongly suggests that ACE-Is and ANG receptor antagonists, in addition to affecting hemodynamics, also influence disease progression through direct inhibition of ANG-induced apoptosis. This manuscript reviews the evidence supporting this view, discusses its potential relevance to disease pathogenesis and offers new hypotheses regarding novel uses of ACE-Is and ANG receptor antagonists in the control of cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570788     DOI: 10.2174/1381612033455477

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  10 in total

Review 1.  Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling.

Authors:  Gerald W Dorn
Journal:  Cardiovasc Res       Date:  2008-09-08       Impact factor: 10.787

2.  The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis.

Authors:  Amal Abdul-Hafez; Tarek Mohamed; Hanan Omar; Mohamed Shemis; Bruce D Uhal
Journal:  J Lung Pulm Respir Res       Date:  2018-02-27

3.  Molecular and cellular mechanisms of the inhibitory effects of ACE-2/ANG1-7/Mas axis on lung injury.

Authors:  Indiwari Gopallawa; Bruce D Uhal
Journal:  Curr Top Pharmacol       Date:  2014-01-01

4.  Combination stem cell therapy for heart failure.

Authors:  Thomas E Ichim; Fabio Solano; Fabian Lara; Jorge Paz Rodriguez; Octav Cristea; Boris Minev; Famela Ramos; Erik J Woods; Michael P Murphy; Doru T Alexandrescu; Amit N Patel; Neil H Riordan
Journal:  Int Arch Med       Date:  2010-04-14

5.  Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice.

Authors:  Xiaopeng Li; Heather Rayford; Bruce D Uhal
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 6.  The spectrum of myocardial homeostasis mechanisms in the settings of cardiac surgery procedures (Review).

Authors:  Emmanuel Papadakis; Meletios Kanakis; Agapi Kataki; Demetrios A Spandidos
Journal:  Mol Med Rep       Date:  2017-11-28       Impact factor: 2.952

Review 7.  Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.

Authors:  Nicholas E Ingraham; Abdo G Barakat; Ronald Reilkoff; Tamara Bezdicek; Timothy Schacker; Jeffrey G Chipman; Christopher J Tignanelli; Michael A Puskarich
Journal:  Eur Respir J       Date:  2020-07-09       Impact factor: 16.671

Review 8.  Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.

Authors:  Diana Garcia-Del-Barco; Daniela Risco-Acevedo; Jorge Berlanga-Acosta; Frank Daniel Martos-Benítez; Gerardo Guillén-Nieto
Journal:  Front Immunol       Date:  2021-03-26       Impact factor: 7.561

9.  Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients.

Authors:  Pavel Osmancik; Elena Teringova; Petr Tousek; Petra Paulu; Petr Widimsky
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

10.  Oxygen injury in neonates: which is worse? hyperoxia, hypoxia, or alternating hyperoxia/hypoxia.

Authors:  Tarek Mohamed; Amal Abdul-Hafez; Ira H Gewolb; Bruce D Uhal
Journal:  J Lung Pulm Respir Res       Date:  2020-01-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.